PF-06414300 for Healthy Subjects
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to learn about how different amounts of study medicine called PF-06414300 acts and is changed and eliminated from the body of healthy adult participants. The amount of PF-06414300 in blood after the medicine is taken by mouth will also be measured.The study is seeking for participants who:* Are male or female of 18 to 65 years of age.* Are in good health condition.* Have body mass index of 16 to 32 kilograms per squared meters; and a total body weight of more than 50 kilograms (110 pounds).All participants in this study will receive either PF-06414300 or placebo (dummy pill) by chance. The study will have 2 parts; in the first part of the study (Part A), each participant will receive a total of 4 doses of PF-06414300 or placebo with at least 10 to 14 days between each dose. After each dose, participants will stay in study clinic for 4 to 5 days.In the second part of the study (Part B), each participant will receive a total of 10 doses of PF-06414300 or placebo and participants will stay in study clinic for 14 days.An optional Japanese cohort may be done later. The planned duration of participation from screening to follow up in Part A and B of this study is up to 12 to 14 weeks and 10 to 12 weeks, respectively.Participants will also have their blood collected by the study doctors several times.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, since the study is for healthy participants, it's possible that taking other medications might not be allowed. Please check with the study team for specific guidance.
What data supports the idea that PF-06414300 for Healthy Subjects is an effective drug?
The available research does not provide any specific data or studies about the effectiveness of PF-06414300 for Healthy Subjects. The articles listed focus on other topics, such as patient outcomes after femoral neck fracture, formulary changes, medication access in low-income populations, lipid testing in elderly patients, and heart failure management. Therefore, there is no direct evidence from these sources to support the effectiveness of PF-06414300 for Healthy Subjects.12345
Who Is on the Research Team?
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Are You a Good Fit for This Trial?
This trial is for healthy adults aged 18-65 with a BMI of 16-32 and weight over 50 kg. It's not suitable for those outside this age range, with health issues, or who don't meet the bodyweight criteria.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Part A
Participants receive 4 doses of PF-06414300 or placebo with 10 to 14 days between each dose, staying in the clinic for 4 to 5 days after each dose
Treatment Part B
Participants receive 10 doses of PF-06414300 or placebo, staying in the clinic for 14 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- PF-06414300
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University